Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Welcome to Ablynx

Ablynx is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases. Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. The unique structure and stability of Nanobodies® has allowed Ablynx, and its partners, to pursue targets that are typically difficult to reach with conventional antibodies.

 

Latest news

08/03/2010
ABLYNX INTENDS TO RAISE UP TO €57.5 MILLION WITH SECONDARY PUBLIC OFFERING - PRICE RANGE: €7.20 - €7.75 PER SHARE

25/02/2010
ABLYNX PLANS A SECONDARY PUBLIC OFFERING ON EURONEXT BRUSSELS

25/02/2010

ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS

22/02/2010

ABLYNX RESPONDS TO PRESS REPORTS

 

 

more news